Urea cycle disorders (UCD) represent a group of rare genetic metabolic disorders characterized by defects in the urea cycle, leading to waste accumulation and toxic levels of ammonia in the blood. Symptoms of UCDs include lethargy, vomiting, and neurological deficits. Various treatment options for UCDs include dietary therapy, alternative pathways medication, ammonia scavenger medication, and liver transplant.
Market key trends:
New product launches by major companies are expected to drive the growth of Urea Cycle Disorder Treatment market over the forecast period. For instance, in September 2020, Horizon Therapeutics plc received US Food and Drug Administration (FDA) approval for Ravicti (glycerol phenylbutyrate) oral liquid for labeling describing use in pediatric patients ages 2 months and older for chronic management of UCDs. Ravicti help lower blood ammonia levels in patients with UCDs. Such new product approvals providing effective treatment options are increasing the overall adoption of UCD treatments, thereby fueling market growth.
Segment Analysis
The global urea cycle disorder treatment market is segmented on the basis of type, treatment, end user and distribution channel. By type, the market is dominated by carbamoyl phosphate synthetase deficiency (CPS), which accounted for around 25% share in 2021. This segment is expected to retain its dominance during the forecast period as it is the most common form of urea cycle disorder.
Key Takeaways
The Global Urea Cycle Disorder Treatment Market Size is expected to witness high growth during the forecast period of 2024 to 2031. The global Urea Cycle Disorder Treatment Market is estimated to be valued at US$ 1518.51 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2024 to 2031.
North America currently dominates the market and is expected to continue dominating with the highest growth rate during the forecast period. This can be attributed to increasing awareness regarding urea cycle disorders and strong presence of key pharmaceutical companies in the region. Europe is also expected to grow at a significant rate during the forecast period due to rising healthcare expenditure and growing research activities regarding rare diseases in countries like Germany, France and United Kingdom. Moreover, presence of supporting patient organizations is also driving the market growth in the region.
Key players related content comprises
Key players operating in the urea cycle disorder treatment market are Charles River, Roche, Agilent Technologies, Inc., among others. Charles River is one of the leading players focussed on developing novel treatment options for carbamoyl phosphate synthetase deficiency through its research activities. Similarly, Roche and Agilent Technologies are engaged in developing robust diagnostics for precise detection and management of various urea cycle disorders.
Explore more information on this topic, Please visit -
https://www.insightprobing.com/urea-cycle-disorder-treatment-market-share-and-demand-analysis/
Explore more trending article related this topic -
Comments
0 comment